Pereira H, Silva S, Julião R, Garcia P, Perpétua F
Department of Pathology, Santa Marta Hospital, Rua de Sta. Marta, 1150 Lisbon, Portugal.
World J Surg. 1997 Feb;21(2):210-3. doi: 10.1007/s002689900218.
P53 is a tumor suppressor gene that has been implicated in the pathogenesis of a wide range of tumor types including colorectal cancers. bcl2 is a proto-oncogene that inhibits apoptosis. Immunostaining for P53 and BLC2 protein product was performed in a retrospective series of 80 colorectal carcinomas with a minimum follow-up of 5 years. The aim of the study was to evaluate the prognostic significance of P53 and BCL2 protein expression and their correlation with clinicopathologic variables such as pathologic disease stage (Dukes system), histologic grade, and vascular invasion. The patients were 41 to 76 years of age, and the follow-up ranged between 5 and 10 years. Among the 80 cases, 30 were Dukes stage A and 50 stage B. We found vascular invasion in 21.2%. P53 and BCL2 expression was detected, respectively, in 30.0% and 8.8%. We concluded that the P53 and BCL2 expression detected by immunohistochemistry in routinely processed, paraffin-embedded tissues: (1) has no prognostic significance; and (2) was not correlated with pathologic disease stage, histologic grade, or vascular invasion. Nevertheless, the number of patients in our study was small, and we believe that investigation of a larger series of patients is indicated.
P53是一种肿瘤抑制基因，与包括结直肠癌在内的多种肿瘤类型的发病机制有关。bcl2是一种抑制细胞凋亡的原癌基因。对80例结直肠癌进行了回顾性研究，对其P53和BLC2蛋白产物进行免疫染色，这些患者的最短随访时间为5年。该研究的目的是评估P53和BCL2蛋白表达的预后意义，以及它们与病理疾病分期（杜克系统）、组织学分级和血管侵犯等临床病理变量的相关性。患者年龄在41至76岁之间，随访时间为5至10年。在80例病例中，30例为杜克A期，50例为B期。我们发现21.2%的病例存在血管侵犯。P53和BCL2表达的检测率分别为30.0%和8.8%。我们得出结论，在常规处理的石蜡包埋组织中通过免疫组织化学检测到的P53和BCL2表达：（1）没有预后意义；（2）与病理疾病分期、组织学分级或血管侵犯无关。然而，我们研究中的患者数量较少，我们认为需要对更多患者进行研究。
